Novo Nordisk (NVO)
(Delayed Data from NYSE)
$118.01 USD
-1.06 (-0.89%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $117.96 -0.05 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$118.01 USD
-1.06 (-0.89%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $117.96 -0.05 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Zacks News
Novo Nordisk (NVO) Stock Moves -0.89%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $118.01, denoting a -0.89% change from the preceding trading day.
Should You Buy AbbVie Stock After Recent Parkinson's Study Success?
by Kinjel Shah
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
by Zacks Equity Research
RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.
PFE vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
Is It Worth Investing in Novo Nordisk (NVO) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study
by Zacks Equity Research
2seventy bio and partner BMY decide to stop enrollment in the late-stage study on Abecma due to growth in the newly diagnosed multiple myeloma treatment space.
The Zacks Analyst Blog Highlights Broadcom, Novo Nordisk, ConocoPhillips, Smith-Midland Corp. and Tredegar
by Zacks Equity Research
Broadcom, Novo Nordisk, ConocoPhillips, Smith-Midland Corp. and Tredegar are part of the Zacks top Analyst Blog.
Top Research Reports for Broadcom, Novo Nordisk & ConocoPhillips
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Novo Nordisk A/S (NVO) and ConocoPhillips (COP), as well as two micro-cap stocks Smith-Midland Corp. (SMID) and Tredegar Corp. (TG).
Novo Nordisk (NVO) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Novo Nordisk (NVO) closed at $125.44 in the latest trading session, marking a +1.41% move from the prior day.
VTYX Stock Rises on Strategic Equity Investment Deal With SNY
by Zacks Equity Research
Ventyx stock climbs 7% on signing a $27 million strategic investment agreement with Sanofi in exchange for granting exclusive rights to VTX3232.
NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study
by Zacks Equity Research
Novo Nordisk stock falls 5.5% on unsatisfactory safety and efficacy data from a mid-stage study of investigational obesity candidate, monlunabant.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?
by Ahan Chakraborty
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.
NVO Gets Positive CHMP Opinion for Wegovy's Label Update in EU
by Zacks Equity Research
Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms and improved physical function.
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?
by Kinjel Shah
SNY's reasonable valuation, rising estimates, improving top line and positive pipeline progress are good enough reasons to stay invested in the stock.
Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?
by Kinjel Shah
PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.
Novo Nordisk (NVO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Novo Nordisk (NVO) concluded the recent trading session at $132.06, signifying a +0.05% move from its prior day's close.
Tap the Weight-Loss Drug Market With These ETFs
by Sweta Killa
Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
by Kinjel Shah
Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.
Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More
by Kinjel Shah
FDA approves J&J's Tremfya for ulcerative colitis. NVO's oral obesity pill, amycretin, shows faster weight loss than weekly injection, Wegovy.
Novo Nordisk (NVO) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
Novo Nordisk (NVO) reachead $136.66 at the closing of the latest trading day, reflecting a +1.06% change compared to its last close.
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
by Kinjel Shah
Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.
Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy
by Zacks Equity Research
NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.
Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug
by Zacks Equity Research
RHHBY's data on experimental obesity drug, CT-996, disappoints investors on higher incidence of adverse events.
PFE or NVO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?